For Q1 FY2026 (ended March 31, 2026), Progyny reported revenue of $328.5 million, up 1.4% year-over-year. Net income rose 60.9% to $24.2 million, with diluted EPS of $0.29, up 70.6%. Operating income increased 46.4% to $35.4 million. The company had $131.6 million in cash and $439.3 million in equity, with no long-term debt.
•Revenue grew 1.4% YoY to $328.5M.
•Net income surged 60.9% to $24.2M.
•Diluted EPS increased 70.6% to $0.29.
•Cash and equity stood at $131.6M and $439.3M, respectively; no long-term debt.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Progyny, Inc., a benefits management company provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle. Its portfolio also includes personalized concierge-style member support services, and a selective network of fertility specialists
Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions.
Additionally, it provides assistance service program where various services can be offered through a reimbursement program Including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. Incorporated in 2008 and headquartered in New York, New York, Progyny was formerly known as Auxogyn, Inc. before rebranding in 2015.
Progyny, Inc. is a benefits management company that provides fertility, family building, and women's health benefits solutions in the United States. Its core offering is a differentiated benefits plan design that includes a smart cycle treatment bundle for fertility treatments. The company also offers personalized concierge-style member support services and a selective network of fertility specialists. Additionally, Progyny provides Progyny Rx, an integrated pharmacy benefits solution that gives access to medications needed during treatment, along with care management services. Its portfolio extends to pregnancy and postpartum care, menopause and midlife solutions, benefit and leave navigation, and parent and child wellbeing solutions. Furthermore, Progyny offers an assistance service program that includes reimbursement for adoption, surrogacy, doula services, and travel when required for medical services.
Where is Progyny listed and what currency does it trade in?
Progyny, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol PGNY. The company trades in United States Dollars (USD). As a US-based company, its stock is denominated in USD, which is the standard currency for equities listed on US exchanges. Investors looking to trade Progyny shares would typically do so through US brokerage accounts, and the stock price is quoted in USD. The NasdaqGS is a major US stock exchange known for listing technology and growth-oriented companies, and Progyny's presence there reflects its status as a publicly traded healthcare benefits firm.
What sector and industry does Progyny operate in?
Progyny, Inc. operates in the Healthcare sector, specifically within the Healthcare Plans industry. This classification means the company is involved in providing health insurance or health benefits plans, focusing on fertility, family building, and women's health. As a healthcare plans company, Progyny designs and manages benefits programs that employers offer to their employees, covering treatments and services related to reproductive health. Unlike traditional health insurers, Progyny specializes in niche areas such as fertility treatments and family building, offering a targeted network of specialists and personalized support. Its industry position places it among companies that administer health benefits, often working with self-insured employers to manage costs and improve outcomes for specific health conditions.
Where is Progyny headquartered and what markets does it serve?
Progyny, Inc. is headquartered in New York, New York, United States. The company was incorporated in 2008 and originally operated under the name Auxogyn, Inc. before rebranding to Progyny in 2015. Its services are exclusively provided within the United States, as indicated by its description summary. Progyny serves employers and their employees across the country, offering fertility and family building benefits as part of corporate health plans. By focusing on the US market, the company tailors its solutions to the American healthcare system, working with a network of fertility specialists and pharmacies to deliver its services. The headquarters in New York positions it in a major financial and business hub, facilitating partnerships with large employers and health plans.
How does Progyny make money?
Progyny generates revenue primarily by providing fertility, family building, and women's health benefits solutions to employers. Its business model involves designing and administering benefits plans that include a smart cycle treatment bundle for fertility treatments, which is a bundled payment model that helps employers manage costs while offering comprehensive coverage. The company also earns fees from its personalized concierge-style member support services and from its selective network of fertility specialists. Additionally, Progyny Rx, an integrated pharmacy benefits solution, generates revenue through the management and dispensing of fertility medications. The assistance service program, which offers reimbursement for adoption, surrogacy, doula, and travel expenses, may also contribute to revenue through administrative fees. Overall, Progyny's revenue is derived from the fees it charges employers for managing these specialized health benefits.